IL10 and metabolic dysfunction-associated steatotic liver disease: Compared to normal controls, NAFLD patients, as well as those with autoimmune hepatic diseases and MTX-related toxicity, presented with lower IL-10 expression levels that, however, did not reach the level of statistical significance (Table 2).